| Market Cap | 734.22M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | 1.59M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -5.00% |
| Sales | 83.47M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -12.00% |
| Dividend | N/A | Price/Book | 11.54 | EPS next 5Y | - | 52W High Chg | -41.00% |
| Recommedations | - | Quick Ratio | 4.35 | Shares Outstanding | 690.23M | 52W Low Chg | 17.00% |
| Insider Own | 11.34% | ROA | -1.10% | Shares Float | 610.43M | Beta | 1.60 |
| Inst Own | 13.40% | ROE | 2.42% | Shares Shorted/Prior | -/- | Price | 1.05 |
| Gross Margin | 83.12% | Profit Margin | 1.91% | Avg. Volume | 403 | Target Price | - |
| Oper. Margin | -0.27% | Earnings Date | - | Volume | 10,000 | Change | 0.00% |
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.